Radiation Oncology Market (2026 - 2033) Size, Share & Trends Analysis Report By Treatment (Internal Beam Radiation Therapy, Systemic Targeted Radiation Therapy), By Technology, By Application, By Target Customer (Academic & Research Cancer Centers, Private Oncology Chains), By Region, And Segment Forecasts

Radiation Oncology Market Summary

The global radiation oncology market size was estimated at USD 14.03 billion in 2025 and is projected to reach USD 33.09 billion by 2033, growing at a CAGR of 11.42% from 2026 to 2033. This growth is driven by the rising prevalence of cancer and increasing demand for effective, targeted treatment options.

Advancements in technologies such as intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and proton therapy are enhancing treatment precision and outcomes. In addition, expanding healthcare infrastructure, growing adoption in emerging markets, and increased investments in oncology care are further supporting market expansion worldwide.

The global radiation oncology industry is primarily driven by the rising incidence of cancer worldwide, which continues to place significant pressure on healthcare systems to expand treatment capacity and adopt advanced therapeutic solutions. Factors such as aging populations, sedentary lifestyles, tobacco use, and environmental exposures have contributed to a steady increase in cancer diagnoses, making radiation therapy a critical component of modern oncology care. According to the World Health Organization in 2022, there were approximately 9.7 million cancer-related deaths globally, with 53.5 million people living within five years of a diagnosis. The organization also highlighted that 1 in 5 individuals develop cancer during their lifetime, with major cancers such as lung (2.5 million cases), breast (2.3 million), and colorectal (1.9 million) driving substantial demand for effective treatment technologies, including radiation therapy.

The growing burden of cancer, including a significant proportion linked to preventable risk factors, is further accelerating the adoption of radiation oncology solutions. In February 2026, the World Health Organization reported that around 37% of global cancer cases, equivalent to 7.1 million cases, were associated with modifiable risk factors such as tobacco use, alcohol consumption, obesity, and environmental exposures. This rising prevalence of lifestyle-related cancers is increasing the need for precise and effective treatment modalities. Radiation therapy plays a crucial role across multiple stages of cancer management, including curative, adjuvant, neoadjuvant, and palliative care, thereby expanding its utilization across hospitals and specialized cancer centers globally. The increasing number of cancer cases is also evident in major markets such as the U.S., where the American Association for Cancer Research estimated 2,041,910 new cancer cases and 618,120 deaths in 2025, highlighting the growing reliance on advanced oncology treatments.

Technological advancements in radiation therapy are significantly transforming the market by improving treatment precision, efficiency, and patient outcomes. Innovations such as image guided radiotherapy (IGRT), intensity modulated radiotherapy (IMRT), stereotactic radiosurgery (SRS), and proton therapy enable highly targeted radiation delivery while minimizing damage to surrounding healthy tissues. For instance, in March 2026, researchers introduced an AI-based radiotherapy framework (AIRT) capable of generating prostate treatment plans in under one second using a single NVIDIA A100 GPU, demonstrating the growing integration of artificial intelligence in treatment planning. Similarly, in March 2025, Elekta showcased its AI-powered adaptive CT-Linac platform, enabling real-time treatment adjustments, while in September 2024, a compact proton therapy center developed by Mevion Medical Systems was announced in the U.S., reflecting the ongoing shift toward more precise and space-efficient radiotherapy solutions.

In addition to technological progress, increasing investments in oncology infrastructure are playing a vital role in supporting market growth. Governments and private healthcare providers are actively expanding radiotherapy capacity through funding initiatives, equipment upgrades, and the development of specialized cancer centers. For instance, in June 2025, the UK government announced an investment of about USD 88 million to replace linear accelerator machines across 28 hospitals, while international efforts such as the International Atomic Energy Agency’s collaboration in February 2025 aimed to establish radiotherapy infrastructure in underserved regions like the Democratic Republic of the Congo. Private sector contributions, including NTPC Limited’s USD 2.8 million investment to upgrade radiotherapy services in India, further highlight the growing commitment to strengthening cancer care infrastructure. These combined efforts, along with improved screening and early diagnosis, are expanding access to radiation therapy and driving sustained growth in the global radiation oncology industry.

Market Concentration & Characteristics

Innovation in the radiation oncology industry remains moderate to high, driven primarily by continuous advancements in radiotherapy technologies, imaging systems, and software-driven treatment planning solutions. The market is characterized by the evolution of external beam radiation therapy (EBRT), brachytherapy, and emerging modalities such as radioligand therapy and particle therapy, which are expanding the scope of cancer treatment. Increasing integration of artificial intelligence, adaptive radiotherapy, and real-time imaging is significantly improving treatment precision and workflow efficiency. For instance, as highlighted in the report, in January 2026, Elekta received FDA clearance for its AI-enabled Elekta Evo CT-Linac system, enhancing tumor visualization and treatment accuracy, while ongoing innovations such as AI-driven planning and real-time tumor tracking are reshaping clinical outcomes and operational efficiency. 

The market for radiation oncology exhibits a moderately consolidated yet regionally fragmented competitive structure, with a few global players dominating developed markets while local and regional players gaining traction in emerging economies. Key companies such as Varian Medical Systems, Elekta AB, Siemens Healthineers, and Accuray Incorporated compete through advanced radiotherapy systems, including linear accelerators, stereotactic radiosurgery platforms, and image-guided technologies. Strategic initiatives such as product launches, partnerships with oncology centers, and clinical collaborations are more prominent than aggressive mergers and acquisitions. For instance, collaborations like Elekta’s MR-Linac consortium and partnerships with hospitals are supporting clinical evidence generation and technology adoption, strengthening competitive positioning across regions.

The regulatory landscape plays a critical and stringent role in shaping the market, given the involvement of radiation-emitting medical devices and radioactive materials. Regulatory authorities such as the U.S. FDA, Nuclear Regulatory Commission, and other regional bodies enforce strict approval, safety, and quality standards for radiotherapy equipment and procedures. These regulations ensure patient safety and treatment efficacy but also increase development timelines, capital requirements, and barriers to entry. In addition, variations in reimbursement frameworks and healthcare policies across countries impact technology adoption and accessibility, particularly for advanced treatments such as proton therapy and stereotactic radiotherapy, thereby influencing overall market dynamics.

The market demonstrates moderate substitutability, with multiple internal treatment options available but limited alternatives outside the broader oncology treatment ecosystem. Radiation therapy competes internally across modalities such as EBRT, brachytherapy, stereotactic radiotherapy, and radioligand therapy, depending on tumor type, stage, and clinical requirements. External beam radiation therapy remains dominant due to its widespread applicability and established infrastructure, while advanced techniques such as proton therapy and adaptive radiotherapy are gaining traction for complex and precision-based treatments. Combination approaches integrating radiation therapy with surgery, chemotherapy, and immunotherapy are also increasing, reflecting a shift toward multimodal cancer care and continuously evolving treatment paradigms within the radiation oncology industry.

Treatment Insights

The external beam radiation therapy (EBRT) treatment segment held the largest share of 73.22% in 2025.The segment delivers high-energy radiation beams from a machine outside the patient’s body to target and destroy cancer cells by damaging their DNA. Because EBRT is non-invasive and can be adapted to treat tumors located in various parts of the body, it has become a fundamental component of modern cancer treatment. Globally, radiation therapy is estimated to be required for around 50-60% of cancer patients at some stage of their treatment. As a result, EBRT systems such as medical linear accelerators are widely deployed across hospitals and specialized oncology centers, making this segment a significant contributor to the overall expansion of radiation oncology services. The growing global burden of cancer continues to drive demand for EBRT-based treatments.

The systemic targeted radiation therapy segment is expected to grow at a CAGR of 15.20% during the forecast period, driven by the rapid development of radiopharmaceutical therapies and theranostic technologies. Systemic targeted radiation therapy involves the administration of radioactive drugs that circulate throughout the body and selectively bind to cancer-specific molecular targets. Once attached to tumor cells, these agents emit radiation that damages cancer DNA while limiting exposure to surrounding healthy tissues. This targeted mechanism enables clinicians to treat both primary tumors and metastatic disease simultaneously, making systemic radiation therapies particularly valuable for advanced or difficult-to-treat cancers.

Technology Insights

The intensity-modulated radiotherapy (IMRT) segment held the largest revenue share of 20.38% in 2025, driven by the increasing demand for highly precise and personalized cancer treatments. IMRT utilizes computer-controlled linear accelerators to modulate the intensity of radiation beams, enabling them to conform closely to the three-dimensional shape of tumors while minimizing exposure to surrounding healthy tissues. This high level of precision allows clinicians to deliver higher radiation doses directly to tumors with fewer side effects, significantly improving patient outcomes and quality of life. Continuous advancements in treatment planning software, imaging integration, and linear accelerator technologies are further enhancing the accuracy, efficiency, and accessibility of IMRT, supporting its widespread adoption across hospitals and cancer care centers worldwide.

The upright beam delivery technology segment is expected to grow at the fastest CAGR over the forecast period, driven by the need to improve patient comfort, treatment accuracy, and workflow efficiency. Unlike conventional radiotherapy systems where patients are treated in a supine or prone position, upright beam delivery systems allow patients to be positioned in a seated or standing posture. This approach can provide better anatomical stability for certain tumor sites, particularly in the thoracic and abdominal regions, where organ motion due to breathing can impact treatment precision. In addition, upright positioning can enhance patient comfort, reduce setup time, and improve reproducibility, making it an attractive option for next-generation radiotherapy solutions. Recent developments are accelerating the growth of this segment. For instance, in September 2025, Leo Cancer Care introduced the Grace upright photon therapy system at ASTRO 2025.

Application Insights

The external beam radiation therapy (EBRT) segment held the largest revenue share in 2025, driven by the rising incidence of cancer and the increasing adoption of non-invasive treatment modalities. EBRT remains one of the most widely used forms of radiation therapy, delivering high-energy beams such as X-rays, protons, or electrons from outside the body to precisely target tumor tissues. Its versatility in treating a broad range of cancers-including breast, lung, prostate, head and neck, and gastrointestinal malignancies-makes it a cornerstone of modern oncology care. Continuous advancements in imaging, treatment planning, and delivery technologies are further enhancing the precision, safety, and effectiveness of EBRT, thereby supporting its widespread adoption across both developed and emerging healthcare systems.

The radioligand therapy (RLT) application segment is experiencing notable growth within the oncology landscape, supported by increasing investment and expanding research in targeted radiopharmaceuticals. Radioligand therapy utilizes specialized ligands linked to radioactive isotopes to selectively bind to cancer cells, delivering radiation directly to tumors while minimizing exposure to surrounding healthy tissue. This high level of precision aligns with the broader shift toward personalized and targeted cancer treatment approaches, making RLT an increasingly important modality across multiple cancer indications. As clinical success continues to build and research pipelines expand, the adoption of radioligand therapies is steadily accelerating. For instance, in January 2026, Novartis AG announced plans to establish its fourth radioligand therapy manufacturing facility in the U.S., located in Winter Park, Florida.

Target Customer Insights

The academic & research cancer centers held the largest revenue share of 32.17% in 2025, primarily due to their central role in innovation, clinical trials, and the adoption of advanced treatment technologies. These institutions are at the forefront of integrating cutting-edge radiation techniques such as image-guided radiotherapy, adaptive radiation therapy, and AI-driven treatment planning. Their strong emphasis on precision oncology and personalized treatment approaches is accelerating the demand for advanced radiation oncology solutions. In addition, the increasing volume of oncology research and clinical trials continues to reinforce their importance, as more studies focus on novel therapies and complex cancer indications.

Nuclear medicine and theranostics centers are emerging as a high-growth targeted customer segment within the market, driven by the rapid evolution of precision oncology and radioligand therapy. These centers integrate diagnostic imaging (such as PET and SPECT) with targeted radiopharmaceutical treatments, enabling a “see and treat” approach that improves patient selection and therapeutic outcomes. This dual capability is making theranostics a cornerstone of modern cancer care, particularly for complex and metastatic cancers. As demand for personalized and targeted therapies increases, healthcare systems are increasingly investing in dedicated nuclear medicine and theranostics infrastructure. 

Regional Insights

The radiation oncology industry in North America held the largest revenue share of 46.21% in 2025. This market growth is fueled by technological innovations in radiotherapies, including the adoption of AI that supports treatment planning and precision therapies such as proton therapy. In addition, companies are forming partnerships and collaborations with research institutions to expand their product offerings and grow their market share. For instance, in July 2025, DYN’R The US partnered with Cablon Medical to launch CNERGY Go! in the U.S., a biometric system for radiation oncology clinics.

In addition, research institutions are enhancing collaborations, further fueling the market growth. For instance, in January 2026, the American Society for Radiation Oncology (ASTRO) rebranded its research arm, formerly the Radiation Oncology Institute, as Speed of Light - The ASTRO Foundation. It is aimed to strengthen the research collaboration and funding, accelerating innovation and improving patient care in radiation oncology.

U.S. Radiation Oncology Market Trends

U.S. led the North America market and held the largest revenue share in 2025. The radiation oncology industry in the U.S. is highly competitive and fueled by ongoing innovations and research efforts. Leading companies in the market include Elketa AB, Accuracy Incorporated, and Siemens Healthineers. These firms actively compete in developing radiation therapy systems for cancer treatment. In addition, key players are introducing radiotherapy solutions with advanced features designed to address cancer. These systems utilize imaging and digital technologies to improve treatment accuracy and patient outcomes. Continuous product innovation helps these companies expand their market presence and stand out from competitors' offerings. For instance, in September 2025, Accuracy Incorporated launched the Accuracy Stellar solution, a comprehensive set of tools designed to empower the clinical team to meet the needs of patients undergoing therapy.

Europe Radiation Oncology Market Trends

The radiation oncology industry in Europe is increasing due to a combination of factors. This market includes technologies such as external beam radiation therapy (EBRT), brachytherapy, image‑guided radiation therapy (IGRT), and emerging adaptive and AI‑enabled treatment planning systems. The primary driver for the growth is the increasing incidence of cancer in Europe. For instance, according to the Cancer Atlas report, in 2022, the estimated number of cancer cases reported was 4.1 million, resulting in 1.9 million deaths. In response, increasing numbers of patients diagnosed with breast, prostate, lung, and other cancers are driving the demand for radiation oncology treatments, as radiotherapy often plays a key role in standard cancer care.

The radiation oncology market in the UK is dominated by key companies operating in radiation therapy, such as Varian Medical Systems, Elekta AB, and Accuray Incorporated. Furthermore, companies are gaining an advantage by maintaining a strong presence through launching advanced technology, collaborating with other companies, and participating in national healthcare initiatives. For instance, in June 2025, Varian Medical Systems, Inc., a part of Siemens Healthineers, expanded its global partnership with Icon Group. This partnership includes a USD 18.7 million investment in highly advanced radiotherapy treatment.

The France radiation oncology market is driven by both global medical technology leaders and innovative companies that focus on advanced cancer treatment technology and research. Major global firms have a strong presence in the radiation oncology sector across the country. These companies emphasize innovation in technologies, product launches, and partnerships that improve treatment precision and clinical outcomes efficiency. For instance, in September 2024, the licensing agreement was formed between Sanofi, Radio Medix, and Orano Med for the development of radiotherapies for rare cancers.

Asia-Pacific Radiation Oncology Market Trends

The radiation oncology industry in the Asia Pacific is expanding mainly because of the rising number of cancer cases across the region, driven by factors such as an aging population, lifestyle changes, and overall population growth. These factors lead to more cancer diagnoses, which increases the demand for effective treatments like radiotherapy. As cancer cases keep increasing, hospitals and cancer care centers are expanding radiation oncology services to handle the growing patient load burden. Furthermore, the use of advanced radiation therapy technologies such as image-guided radiation therapy (IGRT), intensity-modulated radiation therapy (IMRT), and proton therapy is enhancing treatment accuracy and outcomes, leading more healthcare providers to adopt these systems. For instance, in December 2025, Medanta installed the advanced Varian EDGE radiation therapy system to enhance its cancer treatment capabilities.

The radiation oncology market in Japan is anticipated to grow over the forecast period. Japan has one of the highest rates of older adults in the world, and cancer risk increases with age. As the number of cancer patients continues to grow, the need for effective treatment options like radiation therapy is also rising. Radiation oncology is widely used to treat various types of cancer, either as a primary treatment or combined with surgery and chemotherapy.

China radiation oncology market is growing mainly due to the rising incidence of cancer and the increasing need for effective treatment options. As cancer cases continue to increase, the demand for radiation therapy has also grown because it is widely used either as a primary treatment or in combination with surgery and chemotherapy. In addition, the Chinese government is investing in improving healthcare infrastructure and expanding access to advanced cancer treatment technologies. Hospitals are increasingly adopting modern radiation therapy systems such as linear accelerators and image-guided radiotherapy, which further supports the growth of the radiation oncology industry in the country.

Latin America Radiation Oncology Market Trends

The radiation oncology market in Latin America is expanding mainly due to the increasing number of cancer cases across the region. A higher cancer burden is creating strong demand for effective treatment methods such as radiotherapy, which is widely used for treating various tumors, including breast, cervical, and prostate cancers. For instance, Brazil’s National Cancer Institute forecasts that Brazil will record about 781,000 new cancer cases annually between 2026 and 2028, up from 704,000 cases in 2023-2025. The rise underscores cancer as a major public health concern, with prostate cancer leading among men and breast cancer among women, while colorectal cancer becomes the second most common type for both genders.

Middle East and Africa Radiation Oncology Market Trends

The radiation oncology market in Latin America is driven by the growing partnerships and collaborations between medical technology companies, scientific nonprofit organizations, and regional healthcare providers. These alliances facilitate the transfer of advanced technologies, training, and expertise to local hospitals and cancer treatment centers. As a result, the region is experiencing improved access to the latest radiation therapy equipment and innovative treatment protocols. Such collaborations enhance the quality of cancer care, help reduce treatment costs, expand healthcare infrastructure, and accelerate the adoption of modern oncology solutions across the region. For instance, in December 2025, the American College of Radiation Oncology (ACRO) partnered with the Saudi Association of Radiation Oncology (SARO) to introduce specialized radiation oncology accreditation in Saudi Arabia. This collaboration aims to raise clinical standards, improve patient safety, and support quality care across the region.

Key Radiation Oncology Company Insights

Some of the leading players operating in the market include Varian Medical Systems, Inc., Elekta AB, IBA (Ion Beam Applications), andAccuray Incorporated. Companies focus on capturing the market by increasing their presence using various business initiatives, such as partnerships & collaborations with government. Moreover, these companies have well established product portfolio, which helps capture major market share.

Mevion Medical Systems, Canon Medical Systems Corporation, Sumitomo Heavy Industries, Ltd. are some of the emerging market participants in the radiation oncology industry. Developing & launching new and improved products that offer faster results, higher accuracy, and easier usability are observed as prevalent operating strategies by these companies. The players may face challenges in penetrating the market due to competition and regulatory hurdles.

Recent Development

• In March 2026, IBA launched myQA MatriXX AiR, the first wireless 2D ionization chamber array for fast patient-specific QA in particle therapy.

• In September 2025, Accuray Inc. introduced Accuray Stellar, an integrated software/hardware solution for automated adaptive radiotherapy in the U.S.

• In September 2025, Sumitomo Heavy announced a technical collaboration with Leo Cancer Care (USA) to develop an upright proton therapy system.

• In January 2025, Mevion Medical delivered the first-ever FIT compact proton therapy system to Stanford Health Care. 

Radiation Oncology Market Report Scope 

Global Radiation Oncology Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global radiation oncology market report based on treatment, technology, application, target customer, and region:

• Treatment Outlook (Revenue, USD Million, 2021 - 2033)

  • External Beam Radiation Therapy (EBRT)

    • Linear Accelerators (LINAC)

    • Stereotactic Radiosurgery (SRS) Systems

    • Tomotherapy Systems

    • Particle Beam Therapy

      • Proton Therapy

      • Heavy-Ion Therapy

  • Internal Beam Radiation Therapy

    • Brachytherapy

      • Low-Dose Rate (LDR) Brachytherapy

        • Seeds

      • High-Dose Rate (HDR) Brachytherapy

        • Afterloaders

        • Applicators

      • Electronic Brachytherapy

  • Systemic Targeted Radiation Therapy

    • Radioligand Therapy (RLT)

      • Beta-Emitting Radioligand Therapies

      • Alpha-Emitting Radioligand Therapies

• Technology Outlook (Revenue, USD Million, 2021 - 2033)

  • Image-Guided Radiotherapy (IGRT)

    • Motion Tracking / Real-Time Tumor Tracking

    • Other

  • Intensity-Modulated Radiotherapy (IMRT)

  • Volumetric Modulated Arc Therapy (VMAT)

  • 3D Conformal Radiation Therapy (3D-CRT)

  • Stereotactic Radiotherapy (SRS / SBRT)

  • Proton Beam Delivery Technology

  • Heavy-Ion Delivery Technology

  • Adaptive Radiotherapy

  • Upright Beam Delivery Technology

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • External Beam Radiation Therapy (EBRT)

    • Prostate Cancer

    • Breast Cancer

    • Lung Cancer

    • Head & Neck Cancer

    • Colorectal Cancer

    • Central Nervous System (CNS) Tumors

    • Others (e.g., Pediatric Cancers)

  • Internal Beam Radiation Therapy

    • Prostate Cancer

    • Gynecological Cancer

    • Cervical Cancer

    • Breast Cancer

    • Others (e.g., Penile Cancer)

  • Radioligand Therapy Applications

    • Prostate Cancer

    • Neuroendocrine Tumors

    • Thyroid Cancer

    • Others (e.g., Hematologic Malignancies)

• Target Customer Outlook (Revenue, USD Million, 2021 - 2033)

  • Academic & Research Cancer Centers

  • Government & Public Tertiary Hospitals

  • Private Oncology Chains

  • Specialty Proton / Particle Therapy Centers

  • Nuclear Medicine & Theranostics Centers

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait